RU2020122351A -
Cardiotropic agent with anxiolytic and analgesic properties
- Google Patents
Cardiotropic agent with anxiolytic and analgesic properties
Download PDF
Info
Publication number
RU2020122351A
RU2020122351ARU2020122351ARU2020122351ARU2020122351ARU 2020122351 ARU2020122351 ARU 2020122351ARU 2020122351 ARU2020122351 ARU 2020122351ARU 2020122351 ARU2020122351 ARU 2020122351ARU 2020122351 ARU2020122351 ARU 2020122351A
Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова"filedCriticalФедеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова"
Priority to RU2020122351ApriorityCriticalpatent/RU2773018C2/en
Priority claimed from RU2020122351Aexternal-prioritypatent/RU2773018C2/en
Publication of RU2020122351ApublicationCriticalpatent/RU2020122351A/en
Publication of RU2020122351A3publicationCriticalpatent/RU2020122351A3/ru
Application grantedgrantedCritical
Publication of RU2773018C2publicationCriticalpatent/RU2773018C2/en
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Claims (1)
Применение тригидрохлорид N1-(2,3,4-триметоксибензил)-N2-{2-[(2,3,4-триметоксибензил)амино]этил}-1,2-этандиамина, обладающего кардиотропным действием, в качестве анальгетического и анксиолитического средства.The use of trihydrochloride N 1 - (2,3,4-trimethoxybenzyl) -N 2 - {2- [(2,3,4-trimethoxybenzyl) amino] ethyl} -1,2-ethanediamine, which has a cardiotropic effect, as an analgesic and anxiolytic agent.
RU2020122351A2020-07-06Cardiotropic agent with anxiolytic and analgesic properties
RU2773018C2
(en)
Compounds derived from n- (pyridin-3-yl) -1,3-thiazole-5-amino-4-carboxamide, pim kinase inhibitors; pharmaceutical composition; and use for the treatment of cancer.
Compounds derived from pyrazolic heterobicycles, inhibitors of thyroxine kinase protein activity; pharmaceutical composition comprising said compounds; and use of the compounds in the treatment of a hyperproliferative disease.
Compounds derived from pyridin-3-yl-oxypyridin-2-yl-amino, alk5 inhibitors; pharmaceutical composition comprising said compound; and use of the compound in the treatment of cancer.
Compounds derived from n- (2-amino-phenyl) -acrylamides, histone deacetylase inhibitor (hdac); preparation procedure; pharmaceutical composition comprising said compound; and use of the compound for the treatment of cancer.
USE OF AGOMELATIN OR N- [2- (7-METOXI-1-NAFTIL) ETHYL] ACETAMIDE FOR THE TREATMENT OF SMITH MAGENIS SYNDROME; PHARMACEUTICAL COMPOSITION CONTAINING AGOMELATINE.